ClinicalTrials.gg
RecruitingNCT07157345Updated Sep 5, 2025

Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease

A Phase 1 interventional study of PDR001 in Parkinson Disease (PD), sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Ruijin Hospital · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Parkinson Disease by Ruijin Hospital — 8 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · Ruijin Hospital.

Planned enrollment
13th of 18
12 · median 29
Started
2025
with 4 others
Phase 1
2 of 20
2 open now
Registered
16th of 20
by date

Among the 20 studies in Parkinson Disease by Ruijin Hospital, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1, and was the 16th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

8 of the 20 studies in Parkinson Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Parkinson Disease by Ruijin Hospital, or all of them as a file.
02

Study summary

Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary drivers of PD pathogenesis. While siRNA-mediated knockdown of α-synuclein can offer some protection to dopaminergic neurons, its clinical utility is hampered by low cellular uptake, off-target effects, and transient activity. These drawbacks underscore the urgent need for novel strategies that can efficiently and specifically degrade α-synuclein to delay or even halt PD progression.

Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein. When packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus, this peptide effectively reduces α-synuclein within the target region. Pre-clinical studies in both human-α-synuclein-expressing mice and non-human primate models of PD have demonstrated robust α-synuclein clearance and marked improvements in motor deficits (see Research Foundation).

The present project will advance PDR-001 into first-in-human studies to evaluate safety and explore preliminary efficacy. Unlike conventional symptomatic therapies, this approach targets the root cause of PD, setting the stage for disease-modifying treatment. Successful translation would establish a new therapeutic paradigm capable of slowing or preventing PD progression.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • PDR-001
  • Parkinson disease
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

To be eligible for inclusion in this clinical study, all of the following criteria must be met:

  1. Clinically confirmed diagnosis of primary PD (in accordance with the 2016 Chinese Diagnostic Criteria for Parkinson's Disease or the 2015 MDS Clinical Diagnostic Criteria for primary PD);
  2. Age 40-65 years (inclusive) at screening, either sex;
  3. Disease duration ≤ 5 years;
  4. Hoehn \& Yahr stage ≤ 2 in the "off" state.

Exclusion Criteria:

Exclusion Criteria

  1. Atypical or secondary parkinsonian syndromes (e.g., Parkinson-plus syndromes, hereditary parkinsonism, drug-induced parkinsonism, etc.).
  2. to surgery, or any prior intracranial procedure such as deep-brain stimulation, pallidotomy, or other extrapyramidal surgery, or any other neurosurgical intervention deemed by the investigator to interfere with study participation.
  3. Previous neuroimaging revealing structural brain abnormalities, cerebral vascular malformations, intracranial tumors, risk of intracranial hemorrhage, traumatic brain injury, or other significant findings.
  4. (MMSE) score \< 24.
  5. Patient Health Questionnaire-9 (PHQ-9) score ≥ 16.
  6. Abnormal hepatic or renal function: (AST) or alanine aminotransferase (ALT) > 1.5 × (ULN), or serum creatinine (Cr) > 1.5 × ULN.
  7. Coagulation disorders or current use of anticoagulants.
  8. Positive screening for infectious diseases:

    • surface antigen (HBsAg) or Hepatitis B virus DNA (HBV-DNA) positive;
    • virus RNA (HCV-RNA) positive;
    • (HIV) positive;
    • Positive syphilis serology.
  9. Currently receiving antiviral therapy for hepatitis B or C.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    primary parkinson's disease

    PDR-001 injection, inject once, 0.4 milliliters each time

    Drug: PDR001

Interventions

06

What researchers measure

Primary outcomes

  1. PDR-001 treatment-related adverse events as assessed by CTCAE v5.0

    CTCAE 5.0 records the severity of adverse events, which is divided into grades 1 to 5

    Time frame: From enrollment to the end of treatment at 52 weeks

  2. Titer levels of capsid neutralizing antibodies and binding antibodies against recombinant adeno-associated virus (rAAV) in serum

    Record the titer changes before and after treatment

    Time frame: From enrollment to the end of treatment at 52 weeks

  3. Titer of rAAV vectors in whole blood

    Record the titer changes before and after treatment

    Time frame: From enrollment to the end of treatment at 52 weeks

Secondary outcomes

  1. Evaluation of the use of antiparkinsonian drugs will be assessed using the Levodopa Equivalent Daily Dose (LEDD)

    The total daily dose of antiparkinsonian medication (converted to LEDD, mg/day) will be calculated and compared before and after treatment. A decrease in LEDD indicates reduced drug burden (better outcome), while an increase indicates greater drug requirement (worse outcome).

    Time frame: From enrollment to the end of treatment at 52 weeks

  2. Treatment efficacy will be evaluated using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    This scale has a total score range of 0 to 260, with higher scores indicating more severe motor and non-motor symptoms (worse outcome). Changes in scores before and after treatment will be recorded.

    Time frame: From enrollment to the end of treatment at 52 weeks

  3. Treatment efficacy will be evaluated using the Patient Global Impression - Improvement scale (PGI-I)

    This is a 7-point scale ranging from 1 ("very much improved") to 7 ("very much worse"), with lower scores indicating greater improvement (better outcome). Changes in scores before and after treatment will be recorded.

    Time frame: From enrollment to the end of treatment at 52 weeks

  4. Treatment efficacy will be evaluated using the Clinical Global Impression - Improvement scale (CGI-I)

    This is a 7-point scale ranging from 1 ("very much improved") to 7 ("very much worse"), with lower scores indicating greater clinical improvement (better outcome). Changes in scores before and after treatment will be recorded.

    Time frame: From enrollment to the end of treatment at 52 weeks

  5. Treatment efficacy will be evaluated using the Mini-Mental State Examination (MMSE)

    The total score ranges from 0 to 30, with higher scores indicating better cognitive function (better outcome). Changes in scores before and after treatment will be recorded.

    Time frame: From enrollment to the end of treatment at 52 weeks

  6. Treatment efficacy will be evaluated using the Hamilton Depression Rating Scale (HAM-D, 17-item version)

    The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms (worse outcome). Changes in scores before and after treatment will be recorded.

    Time frame: From enrollment to the end of treatment at 52 weeks

  7. Change in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAM-A)

    The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale with scores ranging from 0 to 56, where higher scores indicate greater severity of anxiety symptoms. Treatment efficacy will be evaluated by the change in HAM-A total score from baseline to 52 weeks

    Time frame: From enrollment to the end of treatment at 52 weeks

  8. Change in sleep-related problems as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2)

    PDSS-2 is a 15-item questionnaire. The total score ranges from 0 to 60, with higher scores indicating worse sleep-related problems. Treatment efficacy will be evaluated by the changes in PDSS-2 from baseline to 52 weeks

    Time frame: From enrollment to the end of treatment at 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2029, 39 months later.

Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 39 months is close to that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Sep 5, 2025
StartEst.
Oct 20, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07157345
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Oct 20, 2025 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 5, 2025

Study contacts

Yi Zhang
Contact
zy12893@rjh.com.cn
64370045

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spartalizumab

Start the discussion